Biopharmaceutical
Therapy
Health

Celgene

$95.24
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.39 (-0.41%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Celgene and other stocks, options, ETFs, and crypto commission-free!

About

Celgene Corporation Common Stock, also called Celgene, is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include REVLIMID, POMALYST, IMNOVID, OTEZLA, ABRAXANE, and VIDAZA. Read More The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.

Employees
8,852
Headquarters
Summit, New Jersey
Founded
1986
Market Cap
67.13B
Price-Earnings Ratio
14.48
Dividend Yield
0.00
Average Volume
7.53M
High Today
$96.02
Low Today
$95.19
Open Price
$95.79
Volume
870.60K
52 Week High
$97.07
52 Week Low
$58.59

Collections

Biopharmaceutical
Therapy
Health
Medical
Cancer Prevention
Biotechnology
Pharmaceutical
Technology

News

Yahoo Finance3h

Why Is Celgene Up 1.4% Since Last Earnings Report?

A month has gone by since the last earnings report for Celgene (CELG). Shares have added about 1.4% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Celgene due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Celgene Q1 Earnings Beat Estimates on Revlimid Sales Scr...

5
Yahoo FinanceMay 24

CELG or VRTX: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Celgene (CELG) and Vertex Pharmaceuticals (VRTX). But which of these two stocks is more attractive to value investors?

135
Seeking AlphaMay 24

Bristol-Myers extends date for exchange offers for Celgene debt to July 8

Bristol-Myers Squibb (NYSE:BMY) has extended the expiration date for its offers to exchange Celgene (NASDAQ:CELG) debt for up to $19.85B of new BMY debt to July 8 from June 3. The amounts of Celgene debt tendered thus far range from 70.65 - 97.79%, depending on the tranche....

88

Earnings

$1.88
$2.10
$2.33
$2.55
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
$2.43 per share
Actual
$2.55 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.